Clinical trials: sponsored by Regeneron Pharmaceuticals
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 9 sites in United States, Belgium
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations
This trial is being done in non-obese healthy participants to compare two different forms of cenvacibart. The main goal of the trial is to learn about the trial medicine and how it is absorbed, modified, and removed from the…
- Trial name
- NCT07876505
- Testing
- Cenvacibart
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants. The purpose of this trial is to learn about how safe and tolerable the experimental drug is.
- Trial name
- NCT06669234
- Testing
- ALN-F1202
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans.
- Trial name
- NCT07526116
- Testing
- REGN22044
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Dyslipidemia
ALN-APOC3 in Adult Participants With Dyslipidemia
This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol)…
- Trial name
- NCT06784349
- Testing
- ALN-APOC3
- Where
- Moldova
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD), Asthma
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
The objective is to evaluate the potential effect of exposure to dupilumab in pregnancy compared to the primary comparison group of disease-matched pregnant women who are not exposed to dupilumab, and the secondary comparison…
- Trial name
- NCT04173442
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides).
- Trial name
- NCT06452771
- Testing
- ALN-ANG3
- Where
- New Zealand
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults
The aim of this clinical trial is to see how safe and tolerable the clinical trial drug (REGN9533) is in healthy participants. This is the first time that REGN9533 will be given to humans.
- Trial name
- NCT06665828
- Testing
- REGN9533
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy, Chronic Stable Illness
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
The primary objectives of the study are: To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273 To evaluate the time…
- Trial name
- NCT04852978
- Testing
- casirivimab+imdevimab, Moderna mRNA-1273 vaccine
- Where
- 6 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy, Chronic Stable Illness
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab The secondary objectives of the study are to: Explore variability in the…
- Trial name
- NCT05181683
- Testing
- Casirivimab+Imdevimab
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments").
- Trial name
- NCT06444178
- Testing
- Aspirin, REGN9933, REGN7508
- Where
- United Kingdom
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy…
- Trial name
- NCT05923424
- Testing
- REGN17092
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.
- Trial name
- NCT06137482
- Testing
- REGN13335
- Where
- New Zealand
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer
A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug"). The aim of this study is to see how safe and tolerable the study drug is in healthy participants.
- Trial name
- NCT05603195
- Testing
- REGN7508 (IV), REGN7508 (SC)
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
The study is researching an experimental drug called REGN7544.The study is focused on healthy adults. The aim of the study is to see how safe and tolerable the study drug is in healthy adults.
- Trial name
- NCT05970718
- Testing
- REGN7544
- Where
- New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
The primary objective is to assess the safety and tolerability of REGN2477 alone and combined with REGN1033. The secondary objectives are to: Assess the effect of REGN2477 alone, REGN1033 alone, and REGN2477 + REGN1033 in…
- Trial name
- NCT02943239
- Testing
- REGN1033, REGN2477
- Where
- 2 sites in New Zealand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals